Karien Bloem

Dr. Karien Bloem


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Journal of Immunological Methods
Verified
Journal Article
Closed access
KBKarien Bloem
Karien Bloem
ALAstrid van Leeuwen
Astrid van Leeuwen
GVGerrit Verbeek
Gerrit Verbeek
MNMichael T. Nurmohamed
Michael T. Nurmohamed
GWGerrit Jan Wolbink
Gerrit Jan Wolbink
TRTheo Rispens
Theo Rispens

4 June 2018 in Bioanalysis
Verified
Journal Article
Closed access
KBKarien Bloem
Karien Bloem
TSTiny Schaap
Tiny Schaap
RBRonald Boshuizen
Ronald Boshuizen
EKEva L Kneepkens
Eva L Kneepkens
GWGerrit J Wolbink
Gerrit J Wolbink
TRTheo Rispens
Theo Rispens
Aim: For assessment of concentrations of biopharmaceuticals, for example, therapeutic drug monitoring, dried blood sampling of capillary blood is a convenient alternative to traditional venepuncture sampling. We investigated an alternative to dried blood spot collection on filter paper: sampling capillary blood using the Mitra® microsampler. Materials and Methods: Therapeutic monoclonal antibodies were spiked in whole blood, sampled using filter paper and Mitra microsampler and concentrations measured using specific ELISAs. Results: Good recoveries of adalimumab, infliximab, ustekinumab, vedolizumab, tocilizumab, natalizumab and rituximab were found up to 1 month of storage at room temperature, averaging 95.2% for the Mitra microsampler and 92.9% for Whatman® paper. Both hemoglobin and potassium yield satisfactory estimates for the volume of the cellular fraction of blood samples in combination with the Mitra microsampler. Conclusion: We established practical protocols for the estimation of serum/plasma c...

22 August 2017 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
EKEva L. Kneepkens
Eva L. Kneepkens
MPMieke F. Pouw
Mieke F. Pouw
GWGerrit Jan Wolbink
Gerrit Jan Wolbink
TSTiny Schaap
Tiny Schaap
MNMichael T. Nurmohamed
Michael T. Nurmohamed
KBKarien Bloem
Karien Bloem

30 March 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SBSophie E. Berends
Sophie E. Berends
GDGeert R. A. M. D'Haens
Geert R. A. M. D'Haens
TSTiny Schaap
Tiny Schaap
AVAnnick de Vries
Annick de Vries
TRTheo Rispens
Theo Rispens
RMRon A. A. Mathôt
Ron A. A. Mathôt
Aims: Therapeutic drug monitoring (TDM) can optimize the efficacy of infliximab (IFX) in patients with inflammatory bowel disease (IBD). Because of the delay between blood samples taken at trough and availability of results, dose adjustments can only be carried out at the next infusion, typically 8 weeks later. Dried blood samples (DBS) performed at home to measure IFX concentrations can reduce the time to adapt dose/dosing interval. Here, we aimed to validate the clinical application of DBS for IFX in IBD patients and to evaluate the feasibility of home sampling.Methods: DBS results from 40 IBD patients on IFX treatment were compared to serum sample results at trough, peak, and 3–5 weeks after IFX infusion. Subsequently, patients performed DBS home sampling one week before the next IFX infusion. These were compared to serum concentrations as predicted by Bayesian analysis.Results: IFX concentrations from finger prick and venous puncture correlate well. DBS IFX concentrations showed high correlation with serum IFX concentrations (Spearman correlation: ≥0.965), without bias. Passing‐Bablok regression for IFX concentrations in DBS from home sampling also showed no bias (intercept: 1.02 mg L−1 (95% CI −1.77–2.04 mg L−1), slope: 0.82 (95% CI 0.63–1.40)), with reasonable correlation (Spearman correlation: 0.671).Conclusions: Timely adjustment of IFX dose/dosing interval can be facilitated by IFX concentration measurement in home‐sampled DBS. DBS is a reliable method to measure IFX and can be used to predict IFX trough concentrations.

5 January 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JJJustin Jacobse
Justin Jacobse
WVWouter Ten Voorde
Wouter Ten Voorde
ATAnushka Tandon
Anushka Tandon
SRStefan Romeijn
Stefan Romeijn
HGHendrika W. Grievink
Hendrika W. Grievink
RCRebecca Ten Cate
Rebecca Ten Cate
Aims: To evaluate feasibility of intradermal (i.d.) adalimumab administration using hollow microneedles, and to compare a single i.d. dose of adalimumab using a hollow microneedle with a single subcutaneous (s.c.) dose using a conventional needle.Methods: In this single‐centre double‐blind, placebo‐controlled, double‐dummy clinical trial in 24 healthy adults we compared 40 mg adalimumab (0.4 mL) administered i.d. using a hollow microneedle with a s.c. dose using a conventional needle. Primary parameters were pain, acceptability and local tolerability; secondary parameters safety, pharmacokinetics and immunogenicity. We explored usability of optical coherence tomography, clinical photography, thermal imaging, and laser speckle contrast imaging to evaluate skin reaction after i.d. injections. In vitro protein analysis was performed to assess compatibility of adalimumab with the hollow microneedle device.Results: While feasible and safe, injection pain of i.d. adalimumab was higher compared to s.c. adalimumab (35.4 vs. 7.9 on a 100‐point visual analogue scale). Initial absorption rate and relative bioavailability were higher after i.d. adalimumab (time to maximum plasma concentration = 95 h [47–120]; Frel = 129% [6.46%]) compared to s.c. adalimumab (time to maximum plasma concentration = 120 h [96–221]). Anti‐adalimumab antibodies were detected in 50% and 83% of the subjects after i.d. and s.c. adalimumab, respectively. We observed statistically significantly more erythema and skin perfusion after i.d. adalimumab, compared to s.c. adalimumab and placebo injections (P < .0001). Cytokine secretion after whole blood lipopolysaccharide challenge was comparable between administration routes.Conclusions: Intradermal injection of adalimumab using hollowing microneedles was perceived as more painful and less accepted than s.c. administration, but yields a higher relative bioavailability with similar safety and pharmacodynamic effects.

1 January 2013 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
KBKarien Bloem
Karien Bloem
JGJuan J. García-Vallejo
Juan J. García-Vallejo
IVIlona M. Vuist
Ilona M. Vuist
BCBrian A. Cobb
Brian A. Cobb
Sandra J. Van VlietSandra J. Van Vliet
Sandra J. Van Vliet
YKYvette van Kooyk
Yvette van Kooyk
The zwitterionic capsular polysaccharide A (PSA) of Bacteroides fragilis is the first carbohydrate antigen described to be presented in major histocompatibility complex (MHC) class II for the induction of CD4+ T cell responses. However, the identity of the receptor mediating binding and internalization of PSA in antigen presenting cells remains elusive. C-type lectins are glycan-binding receptors known for their capacity to target ligands for antigen presentation to T cells. Here, we investigated whether C-type lectins were involved in the internalization of PSA and identified dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) as the main receptor for PSA on human dendritic cells. The induction of PSA-specific T cell proliferation appeared to be completely dependent on DC-SIGN. These data reveal a crucial role for DC-SIGN in the endocytosis and routing of PSA in human dendritic cells for the efficient stimulation of PSA-specific CD4+ T cells.